Device Trial Radar · NCT06630546
Trabecular Microbypass IStent in Patients with Glaucoma
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
May 16, 2022
Primary completion
Apr 30, 2023
Study completion Apr 30, 2023
Sponsor
- Lead sponsor
- Yu-Ting TsaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety and efficacy of phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone in a Taiwanese population, as well as to investigate any differences in outcomes between patients with primary open angle glaucoma (POAG) and those with normal tension glaucoma (NTG). The main question it aims to answer is: • How much do intraocular pressure (IOP) and the number of antiglaucoma medications change after iStent insertion, with subgroup analyses for POAG and NTG? Researchers will compare phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone to see if IOP and the number of antiglaucoma medications decrease. Participants will receive their regular phacoemulsification and decided whether to receive iStent by themselves.
Conditions
- Primary Open Angle Glaucoma (POAG)
- Istent Inject W
- Normal Tension Glaucoma (NTG)
Interventions
first generation iStent (Glaukos, San Clemente, CA, USA) insertionDevice
In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
phacoemulsificationDevice
A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular pressure (IOP) in mmHg or percentage changesTime frame: From enrollment to the end of treatment at 18 months
- glaucoma medication changes in numberTime frame: From enrollment to the end of treatment at 18 months
- Visual acuity changes in LogMAR scaleTime frame: From enrollment to the end of treatment at 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chang Gung Memorial Hospital Linkou Branch
Taoyuan City, No.5, Fuxing St., Guishan Dist.,, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.